BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · IEX Real-Time Price · USD
26.19
+0.26 (1.00%)
At close: Jul 19, 2024, 4:00 PM
26.58
+0.39 (1.49%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for BridgeBio Pharma stock have an average target of 46.83, with a low estimate of 33 and a high estimate of 70. The average target predicts an increase of 78.81% from the current stock price of 26.19.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BBIO stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 6 | 6 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $70 | Buy | Reiterates | $70 | +167.28% | Jul 1, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $50 → $42 | Strong Buy | Maintains | $50 → $42 | +60.37% | Jun 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $43 | Strong Buy | Reiterates | $43 | +64.18% | Jun 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $43 | Strong Buy | Reiterates | $43 | +64.18% | Jun 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $43 | Strong Buy | Reiterates | $43 | +64.18% | May 30, 2024 |
Financial Forecast
Revenue This Year
385.50M
from 9.30M
Increased by 4,043.82%
Revenue Next Year
217.44M
from 385.50M
Decreased by -43.60%
EPS This Year
-2.61
from -3.95
EPS Next Year
-3.00
from -2.61
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 957.9M | 504.9M | 853.6M | 1.7B | 2.9B |
| Avg | 385.5M | 217.4M | 551.6M | 1.2B | 1.9B |
| Low | 206.9M | 113.8M | 220.5M | 672.4M | 1.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 10,196.6% | 31.0% | 292.5% | 216.2% | 142.7% |
| Avg | 4,043.8% | -43.6% | 153.7% | 113.0% | 60.2% |
| Low | 2,124.0% | -70.5% | 1.4% | 21.9% | 2.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.88 | -0.50 | 0.25 | 3.00 | 6.89 |
| Avg | -2.61 | -3.00 | -1.78 | 2.92 | 6.69 |
| Low | -4.09 | -3.71 | -3.40 | 2.80 | 6.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 136.1% |
| Avg | - | - | - | - | 129.4% |
| Low | - | - | - | - | 120.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.